Primary Plasma Cell Leukemia: A Retrospective Study of a Rare Disease From Tertiary Cancer Centre From India

Yadav, Neha; Aggarwal, Mukul; Mehta, Pallavi; Kapoor, Jyotsna; Thekkudan, Shinto Francis; Bhandari, Pragya; Soni, Priyanka; Ahmed, Rayaz; Bhurani, Dinesh; Agrawal, Narendra

doi:10.1007/s12288-019-01114-9

Cited by 3 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lytic lesions on imaging is reported to be lower than in MM; however, it may be found in approximately half of the patients more so those with sPCL [11]. is is illustrated in the first case where the patient had extensive lytic disease, hence the question whether she had sPCL as opposed to pPCL.…”

Section: Epidemiology and Clinical Presentationmentioning

confidence: 95%

“…On physical examination, these patients have a higher prevalence of organomegaly with involvement of the liver and spleen [11]. Other patients may have pleural effusion, neurological deficits due to CNS involvement, or palpable extramedullary soft tissue plasmacytomas.…”

Section: Epidemiology and Clinical Presentationmentioning

confidence: 99%

“…Case Reports in Hematology abnormalities [5,8,15]. Majority of the PCL cases had translocation involving the immunoglobulin heavy-chain locus (IgH) on 14q32 such as t (11,14), t (4; 14), and t (14; 16). TP53 inactivation, MYC translocations, and mutations in K-RAS and N-RAS were among those documented with PTEN deletion which cause Akt activation being more in sPCL.…”

Section: Diagnosismentioning

confidence: 99%

“…Plasma cell leukemia has a poor prognosis in comparison to multiple myeloma [11,14,26]. In addition, the outcome for sPCL is much worse and most studies report survival of few months in comparison to pPCL [9,12,14,27].…”

Section: Prognosismentioning

confidence: 99%

See 3 more Smart Citations

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya

Ong'ondi

Kagotho

2021

Case Reports in Hematology

View full text Add to dashboard Cite

Plasma Cell Leukemia (PCL) is a rare and aggressive form of plasma cell dyscrasia that can arise either de novo (primary plasma cell leukemia) or evolve from previously diagnosed and treated multiple myeloma (secondary PCL). We highlight three clinical cases with very different presentations as a reminder of this diagnosis. The cases also highlight the diversity and variability that cover a patient’s journey that is highly dependent on accessibility based on financial capability and social support. The clinical presentation is more aggressive due to the higher tumour burden and more proliferative tumor cells with cytopenias being profound and more organomegaly. The diagnosis is made based on at least 20% of total white blood cells being circulating plasma cells with a peripheral blood absolute plasma cell count of at least 2 × 109/l. Treatment with novel agents followed by autologous stem cell transplant in those who are transplant eligible leads to better outcomes.

show abstract

Section: Epidemiology and Clinical Presentationmentioning

confidence: 95%

Section: Epidemiology and Clinical Presentationmentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%

Section: Prognosismentioning

confidence: 99%

See 2 more Smart Citations

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya

Ong'ondi

Kagotho

2021

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…[ 5 , 10 ] So, in some studies, a lower diagnostic threshold (i.e., >5% circulating plasma cell and/or >0.5 × 10 9 /L peripheral blood clonal plasma cells) has been proposed. [ 11 – 13 ]…”

Section: Introductionmentioning

confidence: 99%

Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database

Ge¹,

Meng²,

Wang³

et al. 2022

Medicine

View full text Add to dashboard Cite

The primary plasma cell leukemia (pPCL) is a rare but aggressive variant of multiple myeloma (MM). Few studies have focused on the differences in the causes of death between pPCL and MM. This study aimed to compare and evaluate the causes of death of patients with pPCL and MM. The data were collected from the Surveillance Epidemiology, and End Results (SEER) database. The demographic characteristics, survival, and causes of death in pPCL and MM patients were evaluated and compared. The competing risk regression model was performed to predict the cause of death. Between 1975 and 2009, the overall mortality rate was 96.13% and 88.71% for pPCL and MM, and the median survival was 9 and 26 months, respectively. In pPCL, leukemia caused 45.05% of the deaths, followed by myeloma (38.83%). In MM, myeloma was the leading cause of death, accounting for 74.89% of the deaths. Older age at diagnosis was a risk factor for dying of leukemia in pPCL patients (HR = 1.49, 95% CI: 1.16–1.91), while older age at death was associated with reduced risk (HR = 0.67, 95% CI: 0.52–0.86). Although the survival of pPCL patients increased with time periods of diagnosis since 1975 to 2009, the risk of dying of leukemia increased with the periods. For MM, most of the demographic characteristics were found to have independently predicting influence on the cause of death. Patients with pPCL and MM had distinct causes of death. Leukemia was the leading and the most serious cause of death in pPCL patients. The demographic factors could not predict the causes of death in pPCL. More large-scale and multi-center studies are needed to evaluate the effect of novel agents in pPCL patients, especially for patients who have progressed to leukemia.

show abstract

Melphalan

2019

Reactions Weekly

View full text Add to dashboard Cite

Primary Plasma Cell Leukemia: A Retrospective Study of a Rare Disease From Tertiary Cancer Centre From India

Cited by 3 publications

References 20 publications

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya

Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database

Melphalan

Contact Info

Product

Resources

About